Compounds > jaspamide b
Page last updated: 2024-11-12

jaspamide b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

jaspamide B: from marine sponge Jaspis splendans; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

jaspamide B : A cyclodepsipeptide isolated from Jaspis splendens. A derivative of jaspamide, it exhibits anti-tumour activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10747466
CHEMBL ID452984
CHEBI ID66105
MeSH IDM0302833

Synonyms (6)

Synonym
jasplakinolide b
CHEMBL452984
chebi:66105 ,
(4r,7r,10s,13s,17r,19s)-7-[(2-bromo-1h-indol-3-yl)methyl]-4-(4-hydroxyphenyl)-8,10,13,17,19-pentamethyl-15-methylidene-1-oxa-5,8,11-triazacyclononadecane-2,6,9,12,16-pentone
jaspamide b
Q27134620

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In addition, the results of a clonogenic dose-response study on jasplakinolide are presented."( Biostructural features of additional jasplakinolide (jaspamide) analogues.
Amagata, T; Bray, WM; Crews, P; Gassner, NC; Lokey, RS; Media, J; Morinaka, BI; Robinson, SJ; Tenney, K; Valeriote, FA; Watts, KR, 2011)		0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclodepsipeptideA depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring.
organobromine compoundA compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID485983Growth inhibition of human HCT116 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID1296043Cytotoxicity against human ONS cells derived from parkinsons disease patients assessed as alteration of cellular parameters at 10 uM2016Journal of natural products, Feb-26, Volume: 79, Issue:2
A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID592429Antimicrofilament activity in human HCT116 cells assessed as loss of microfilament at 0.05 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592489Antimicrofilament activity in human HCT116 cells assessed as additional loss of microfilament network at 0.5 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592427Anticancer activity against human HCT116 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID485985Growth inhibition of human SF539 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID485986Growth inhibition of human M14 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID485989Growth inhibition of human MCF7 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID666464Growth inhibition of human KB cells after 72 hrs by CellTiter 96 assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Pipestelides A-C: cyclodepsipeptides from the Pacific marine sponge Pipestela candelabra.
AID485981Cytotoxicity against human HeLa cells at 80 nM after 34 hrs by microfilament disruption assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID592491Antimicrofilament activity in human HCT116 cells assessed as complete loss of microfilament network at GI50 concentration by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID378714Cytotoxicity against human NSCLC-N6 cells by MTT assay1999Journal of natural products, Feb, Volume: 62, Issue:2
New jaspamide derivatives from the marine sponge Jaspis splendans collected in Vanuatu.
AID666463Inhibition of cell proliferation of human KB cells at 1 uM after 72 hrs by CellTiter 96 assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Pipestelides A-C: cyclodepsipeptides from the Pacific marine sponge Pipestela candelabra.
AID592514Antimicrofilament activity in human HCT116 cells assessed as additional loss of microfilament at 5 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592509Antimicrofilament activity in human HCT116 cells assessed as additional loss of microfilament at 1 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID485990Growth inhibition of human RPMI8266 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID485984Growth inhibition of human HCT15 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID592430Antimicrofilament activity in human HCT116 cells assessed as loss of microfilament at 0.01 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID592428Anticancer activity against human MDA-MB-231 cells2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID1296042Cytotoxicity against human ONS cells derived from parkinsons disease patients assessed as alteration of nuclear parameters at 10 uM2016Journal of natural products, Feb-26, Volume: 79, Issue:2
A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID592431Antimicrofilament activity in human HCT116 cells assessed as loss of microfilament at 0.1 uM by rhodamine-phalloidin staining2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Biostructural features of additional jasplakinolide (jaspamide) analogues.
AID666462Inhibition of cell proliferation of human KB cells at 10 uM after 72 hrs by CellTiter assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Pipestelides A-C: cyclodepsipeptides from the Pacific marine sponge Pipestela candelabra.
AID485987Growth inhibition of human OVCAR-3 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID485988Growth inhibition of human 786-0 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
AID485982Growth inhibition of human HOP62 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymidine
[no description available]		2.1310pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
toyocamycin
Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.		2.1310antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside		antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
nsc 65346
sangivamycin: RN given refers to parent cpd. sangivamycin : A nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C.		2.1310nucleoside analogueprotein kinase inhibitor
jasplakinolide
jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R*,4E,6S*,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.		3.1550cyclodepsipeptide;
phenols		actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		2.1310guanosines;
purines D-ribonucleoside		fundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Non-Small Cell Lung
[description not available]		0210
Cancer of Lung
[description not available]		0210
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		0210
Lung Neoplasms
Tumors or cancer of the LUNG.		0210
Idiopathic Parkinson Disease
[description not available]		02.1310
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		02.1310